🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Celldex Therapeutics, Inc.

CLDX Healthcare
$31.43 $-0.27 (-0.85%)
Market Cap: $2.47 B
Gurus Holding
4
Popularity Rank
#2242
% of Shares Held
5.46%
Net Activity (Q1 2026)
+$47.26 M

Guru Ownership Trend

Guru Analysis for Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. (CLDX), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q1 2026, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $134.73 M.

Top institutional holders include Steven Cohen and Ken Fisher.

Institutional sentiment is currently Bullish. This is evidenced by a $47.26 M net inflow during the quarter.

Recent activity highlights Paul Tudor Jones who opened a new position.

Key Holders

Top 5 by Value

$102.45 M
$32.15 M
$246,687

Top 5 by Conviction

Recent Activity Breakdown (Q1 2026)

+$50.47 M
Total Buy Value
New Buys 2
Additions 2
-$3.22 M
Total Sell Value
Reductions 0
Sold Out 1

Guru Consensus (Q1 2026)

Based on recent activity
Net Sellers
1
Net Buyers
4

FAQs for Celldex Therapeutics, Inc. (CLDX)

Major holders include Steven Cohen ($102.45 M), Ken Fisher ($32.15 M), Paul Tudor Jones ($1.12 M). According to the latest reported data, 4 tracked investment managers collectively hold approximately 4.29 M shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $47.26 M, with 4 managers increasing positions and 1 managers reducing holdings.

During the most recent reporting period, 0 managers trimmed their positions, while 1 fully exited CLDX. The total reported sell value was $3.22 M.

Yes, 2 managers opened new positions in CLDX, and 2 increased their existing holdings. The total reported buy value was $50.47 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.13% Add 83.7% 3,229,939 $102.45 M Q1 2026
0.01% Add 8.2% 1,013,648 $32.15 M Q1 2026
0.00% New Buy 35,393 $1.12 M Q1 2026
0.00% New Buy 7,777 $246,687 Q1 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form